PRESENTATION

Q1 2023 — Results presentation

Q1 2023PDF · 20 pages1.6 MB


-- 1 of 20 --

1st Quarter 2023
Earnings Call
April 18, 2023

-- 2 of 20 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on
these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as
interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action,
including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in
behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the
health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely
basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health
Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual
Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in
Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
3

-- 3 of 20 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension 	UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 20 --

5
Agenda
Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
1
2
3
4
Ashley McEvoy
Executive Vice President,
Worldwide Chairman,
MedTech
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations

-- 5 of 20 --

Regional Sales Results 	Q1 2023 	Q1 2022
% CHANGE
Reported 	Operational1
U.S. 	$12.5 	$11.4 	9.7% 	9.7%
Europe 	6.3 	6.0 	5.1 	10.0
Western Hemisphere
(ex U.S.) 1.6 	1.5 	7.1 	14.3
Asia-Pacific, Africa 	4.3 	4.5 	(4.3) 	4.1
International 	12.2 	12.0 	1.8 	8.3
Worldwide (WW) 	$24.7 	$23.4 	5.6% 	9.0%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
1st Quarter 2023 Sales
Dollars in Billions
6

-- 6 of 20 --

0.4%; 3.0% 1
Q1 2023 	Q1 2022
1st Quarter 2023 Financial Highlights
Dollars in Billions, except Earnings / (Loss) Per Share
Reported %; Operational % 1
7
Sales
Adjusted Earnings 2 Adjusted EPS2
5.6%; 9.0% 1
GAAP Earnings / (Loss)
(101.3)%
(0.9)%
Q1 2023 	Q1 2022
(101.6)%
Q1 2023	Q1 2023 	Q1 2022 	Q1 2022	Q1 2023 	Q1 2022
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
* Basic Shares are used to calculate the loss per share as use of diluted shares when in a loss position would be anti-dilutive
$24.7 $23.4
($0.1)
$5.1
($0.03)
$1.93
$7.1 	$7.1 $2.68 	$2.67
GAAP Earnings / (Loss)
Per Share (Basic / Diluted)*

-- 7 of 20 --

OTC
$1,642
Skin Health/Beauty
$1,110
Oral Care
$361Baby Care
$359
Women's Health
$217
Wound Care/Other
$164
$3,852
7.4%, 11.3%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
, Note: Values may not add due to rounding
Consumer Health Highlights – 1st Quarter 2023
Operational growth 1 across all franchises and regions primarily driven by OTC and Skin Health
Key Drivers of Operational Performance1
OTC
• 	Growth driven by price actions, exceptionally high Cough/Cold/Flu incidences primarily
in Europe, and one-time supply replenishment primarily in the U.S. reflected in
TYLENOL, MOTRIN, NICORETTE and IMODIUM
Skin
Health/
Beauty
• 	Growth driven by price actions, one-time supply replenishment and sun season
pipeline fill, as well as e-commerce and club channel performance driven by new
product innovations in NEUTROGENA and AVEENO, partially offset by U.S. portfolio
simplification and competitive pressures
Oral Care
• 	Growth driven by U.S. price actions, partially offset by lapping OUS prior year
increased demand and negative impact from suspension of personal care sales in
Russia
Baby Care
• 	Growth driven by price actions, one-time supply replenishment, and lapping PY OUS
reserve true-up, partially offset by negative impact from suspension of personal care
sales in Russia
Women’s
Health
• 	Growth driven by price actions and India strength, partially offset by negative impact
from suspension of personal care sales in Russia
Wound
Care/Other • 	Growth driven by price actions and strong demand in Canada
Adjusted Operational Sales2: WW 11.3%, U.S. 11.4%, Int’l 11.3%
Reported: 	WW 7.4%, U.S. 11.4%, Int’l 4.4%
Operational1: 	WW 11.3%, U.S. 11.4%, Int’l 11.3%
12.4%, 15.8%
(4.8)%, 4.1%
(0.1)%, 2.5%
1.0%, 6.5%
(1.3)%, 2.1%
9.7%, 13.1%
8

-- 8 of 20 --

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
, Note: Values may not add due to rounding
Immunology
$4,112
Infectious Diseases
$1,586
Neuroscience
$1,804
Oncology
$4,112
CVM/Other
$927
PH
$872
$13,413
4.2%, 7.2%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Key Drivers of Operational Performance1
Immunology
• 	STELARA increase driven by market and share growth in both CD and UC, partially offset
by unfavorable patient mix and price
• 	Growth in TREMFYA due to share gains in both PsO and PsA and market growth, partially
offset by unfavorable patient mix
• 	REMICADE decline due to biosimilar competition
Infectious Diseases • 	Driven by COVID-19 Vaccine revenue and EDURANT growth, partially offset by OUS
competition for PREZISTA/PREZCOBIX/REZOLSTA
Neuroscience
• 	SPRAVATO growth driven by ongoing launches in the U.S. and Europe as well as
increased patient demand
• 	Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA driven by new patient starts and
persistency, and launch of INVEGA HAFYERA/BYANNLI, partially offset by the XEPLION
loss of exclusivity in EU
Oncology
• 	DARZALEX increase driven by share gains in all regions, continued market growth, and
strong FASPRO adoption
• 	Continued strong share gains, market growth, and increased penetration from new
launches for ERLEADA
• 	CARVYKTI driven by continued market share gains and ongoing phased launch
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA decline due to
global competitive pressures. Imbruvica maintains its market leadership position
Cardiovascular/
Metabolism/
Other (CVM/Other)
• 	XARELTO increase due to favorable patient mix and market growth, partially offset by
share loss
Pulmonary
Hypertension (PH)
• 	Increase driven by market and volume growth from UPTRAVI and OPSUMIT
• 	Continued declines in Other Pulmonary Hypertension
Adjusted Operational Sales2: WW 7.2%, U.S. 5.9%, Int’l 8.8%
Pharmaceutical Highlights – 1st Quarter 2023
Reported: 	WW 4.2%, U.S. 5.9%, Int’l 2.4%
Operational1: 	WW 7.2%, U.S. 5.9%, Int’l 8.6%
1.8%, 3.0%
2.4%, 5.0%
4.1%, 7.7%
22.3%, 26.4% (0.2)%, 2.5%
Continued strong operational growth 1 driven by key brands
3.6%, 6.1%
9

-- 9 of 20 --

Key Drivers of Operational Performance1
Interventional
Solutions
• 	Electrophysiology: Double digit increases in all regions except Asia Pacific which reflects the impacts of
COVID-19 procedure disruption and volume-based procurement in China
• 	Abiomed: Acquired December 22, 2022; leader in Heart Recovery through commercialization of Impella
Heart Pumps
Orthopaedics
• 	Hips: Growth reflects global procedure recovery and strength across the portfolio (primarily in the Anterior
approach), partially offset by impacts of volume-based procurement in China and supply challenges
• 	Trauma: Growth primarily driven by adoption of recently launched products (Advanced Nailing Systems,
VA Clavicle) partially offset by softer procedure volumes compared to prior year and impacts of volume-
based procurement in China
• 	Knees: Double digit growth reflects global procedure recovery, strength of the ATTUNE portfolio, and pull
through related to the VELYS Robotic assisted solution, partially offset by impacts of volume-based
procurement in China
• 	Spine, Sports & Other: Primarily driven by market growth and positive new product performance in
Digital Solutions, Shoulders and Spine (VELYS Digital Solutions, INHANCE, SYMPHONY), partially offset
by impacts of volume-based procurement in China and continued competitive pressures in Spine
• 	Spine: ~ +2% WW, ~ +4% U.S., ~ -1% OUS
Surgery
• 	Advanced:
• 	Endocutters: ~ -5% Decline primarily due to impacts of volume-based procurement in China,
competitive pressures predominately in the U.S., and supply challenges, partially offset by positive
uptake from recently launched products (ECHELON 3000 and ECHELON STAPLE LINE
REINFORCEMENT)
• 	Biosurgery: ~ +7% Reflects global procedure recovery, strength from new products and a
differentiated portfolio (SURGIFLO, SURGICEL Powder and VISTASEAL)
• 	Energy: ~ +3% Driven by double digit growth in the U.S. with improved procedure volumes and
strength of new products (ENSEAL X1 family), partially offset by impacts of volume-based
procurement in China and product supply challenges
• 	General: Growth driven primarily by improved procedure volumes coupled with technology penetration
and benefits from our differentiated Wound Closure portfolio (Barbed & PLUS Sutures)
Vision
• 	Contact Lenses/Other: Growth driven by the market, continued strong performance in the ACUVUE
OASYS 1-Day family (including recent launches of OASYS MAX 1-day and OASYS Multifocal), and
effective commercial execution, partially offset by supply challenges
• 	Surgical: Growth led by strength in Monofocal IOLs (TECNIS EYHANCE), partially offset by softer
Refractive and premium IOL markets and supply challenges
Adjusted Operational Sales 2: WW 6.4%, U.S. 8.4%, Int’l 4.6%
Orthopaedics
$2,245
Surgery
$2,434
Vision
$1,300
Interventional
Solutions
$1,503
$7,481
7.3%, 11.0%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
MedTech Highlights – 1st Quarter 2023
Operational growth 1 fueled by Abiomed acquisition, market acceleration, and innovation across all franchises
Reported: 	WW 7.3%, U.S. 16.6%, Int’l (0.6)%
Operational1: 	WW 11.0%, U.S. 16.6%, Int’l 6.2%
37.6%, 41.9%
3.4%, 7.6%
2.6%, 5.1%
0.0%, 4.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
, Note: Values may not add due to rounding
10

-- 10 of 20 --

2023 	2022 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$24,746 	100.0 	$23,426 	100.0 	5.6
Cost of products sold 	8,395 	33.9 	7,598 	32.4 	10.5
Gross Profit 	16,351 	66.1 	15,828 	67.6 	3.3
Selling, marketing and administrative expenses 	6,138 	24.8 	5,938 	25.4 	3.4
Research and development expense 	3,563 	14.4 	3,462 	14.8 	2.9
In-process research and development 	49 	0.2 	610 	2.6
Interest (income) expense, net 	(20) 	(0.1) 	(12) 	(0.1)
Other (income) expense, net 	7,228 	29.2 	(102) 	(0.4)
Restructuring 	130 	0.6 	70 	0.3
Earnings / (Loss) before provision for taxes on income 	(737) 	(3.0) 	5,862 	25.0 	(112.6)
Provision for / (Benefit from) taxes on income 	(669) 	(2.7) 	713 	3.0 	(193.8)
Net Earnings / (Loss) 	($68) 	(0.3) 	$5,149 	22.0 	(101.3)
-
Net earnings / (Loss) per share (Basic/Diluted)* 	($0.03) 	$1.93 	(101.6)
Average shares outstanding (Basic/Diluted)* 	2,605.5 	2,666.5
Effective tax rate 	90.8% 	12.2%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$8,468 	34.2 	$8,218 	35.1 	3.0
Net earnings 	$7,068 	28.6 	$7,129 	30.4 	(0.9)
Net earnings per share (Diluted) 	$2.68 	$2.67 	0.4
Average shares outstanding (Diluted)** 	2,634.3 	2,666.5
Effective tax rate 	16.5% 	13.3%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
* Basic shares are used to calculate loss per share as use of diluted shared when in a loss position would be anti-dilutive
** Difference of 28.8 shares due to anti-dilutive impact on new loss position
11
1 st Quarter 2023
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 11 of 20 --

2023 	2022
Adjusted Income Before Tax by Segment1
1 st Quarter 2023
12
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
Q1 2023 	Q1 2022
Pharmaceutical 	43.2% 	44.1%
MedTech 	27.0% 	27.0%
Consumer Health 	22.3% 	22.1%
Total 	34.2% 	35.1%
% to Sales
($0.2) 	($0.1)
$8.2B
$5.6
$1.9
$0.8
$8.5B
$5.8
$2.0
$0.9
2
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 4/18/2023

-- 12 of 20 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 13 of 20 --

14
Notable Announcements in 1st Quarter 2023
1
Pharmaceutical
• 	Regulatory:
– 	Janssen Receives Positive CHMP Opinion for AKEEGA (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated
Metastatic Castration Resistant Prostate Cancer
– 	Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted
Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
• 	Data Release:
– 	Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
– 	Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
– 	Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
– 	TREMFYA (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
– 	New STELARA (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
– 	Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with
Pulmonary Arterial Hypertension (PAH)
– 	TREMFYA (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
– 	New RYBREVANT (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have
Failed Prior Platinum-Based Chemotherapy
• 	Other
– 	Janssen Provides Portfolio Update
– 	ERLEADA (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.2
MedTech
• 	Data Release:
– 	Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR Balloon Ablation Catheter Presented at AF Symposium 2023
– 	First Look at Data on Biosense Webster’s Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023
Enterprise
– 	Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims 2
– 	Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
– 	Johnson & Johnson Names Dr. Paula A. Johnson, President of Wellesley College, to its Board of Directors
– 	Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.
1 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com
2 Subsequent to the Quarter

-- 14 of 20 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions 	Q1 2023
Cash and Marketable
Securities* $33
Debt** 	($53)
Net Debt 	($20)
Free Cash Flow1,2 ~$2.5.
Q1 2023:
$3.6B invested in R&D
$2.9B in dividends paid
to shareholders
Note: values may have been rounded
* Includes $7.7B of Restricted Cash
** Includes $7.7B of Kenvue Debt
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of April 18, 2023. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 Announced $5B share repurchase program on September 14, 2022 	15
Note: values may have been rounded
$2.5B in share repurchases;
100% of the program completed 3

-- 15 of 20 --

1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: April 2023 = $1.10 	6 Excludes COVID-19 Vaccine
Note: Percentages may be rounded 	16
2023 P&L Guidance
April 	January 	Comments
Adjusted Operational Sales1,2,6 	4.5% - 5.5% 	3.5% - 4.5% 	Increasing midpoint to 5.0%
Operational Sales 2,6 	$97.9B - $98.9B
5.5% – 6.5%
$96.9B - $97.9B
4.5% – 5.5% Increasing midpoint by $1B to 6.0%
Estimated Reported Sales 3,6 	$97.9B - $98.9B
5.5% – 6.5%
$96.9B - $97.9B
4.5% – 5.5%
Increasing midpoint by $1B to 6.0%
No FX impact
Adjusted Pre-Tax
Operating Margin4,5 	Approximately flat 	Approximately flat 	Maintain
Net Other Income 4 	$1.9 - $2.1 billion 	$1.9 - $2.1 billion 	Maintain
Net Interest Expense / (Income) 	$250 - $350 million 	$250 - $350 million 	Maintain
Effective Tax Rate 4 	15.5% - 16.5% 	15.5% - 16.5% 	Maintain
Adjusted EPS (Operational) 2,4 	$10.50 - $10.60
3.5% - 4.5%
$10.40 - $10.60
2.5% - 4.5%
Tightening of range;
Increasing midpoint by $0.05
Adjusted EPS (Reported) 3,4 	$10.60 - $10.70
4.5% - 5.5%
$10.45 - $10.65
3.0% - 5.0%
Tightening of range;
Increasing midpoint by $0.10;
Incremental FX +$0.05
Raising top- and bottom-line guidance due to strong Q1 performance

-- 16 of 20 --

Save the Date
Introducing Our
First Ever…
Enterprise
Business
Review
Focused on the New Johnson
& Johnson
Tuesday, December 5, 2023
New York Stock Exchange

-- 17 of 20 --

Q&A
Ashley McEvoy
Executive Vice President,
Worldwide Chairman,
MedTech
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations

-- 18 of 20 --



-- 19 of 20 --

= Achieved

-- 20 of 20 --